
Sign up to save your podcasts
Or
Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations.
CME information and select publications here.
4.4
3030 ratings
Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations.
CME information and select publications here.
17 Listeners
14 Listeners
65 Listeners
11 Listeners
72 Listeners
0 Listeners
6 Listeners
325 Listeners
38 Listeners
113 Listeners
58 Listeners
122 Listeners
43 Listeners
27 Listeners
56 Listeners
88 Listeners
169 Listeners